187 related articles for article (PubMed ID: 23666879)
21. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity.
Takakusa H; Masumoto H; Yukinaga H; Makino C; Nakayama S; Okazaki O; Sudo K
Drug Metab Dispos; 2008 Sep; 36(9):1770-9. PubMed ID: 18508880
[TBL] [Abstract][Full Text] [Related]
22. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.
Thompson RA; Isin EM; Li Y; Weaver R; Weidolf L; Wilson I; Claesson A; Page K; Dolgos H; Kenna JG
Chem Biol Interact; 2011 Jun; 192(1-2):65-71. PubMed ID: 21074519
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of drug toxicity and relevance to pharmaceutical development.
Guengerich FP
Drug Metab Pharmacokinet; 2011; 26(1):3-14. PubMed ID: 20978361
[TBL] [Abstract][Full Text] [Related]
24. Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity.
Hirayama N
Drug Metab Pharmacokinet; 2017 Feb; 32(1):31-39. PubMed ID: 27964952
[TBL] [Abstract][Full Text] [Related]
25. Failed Pediatric Drug Development Trials.
Momper JD; Mulugeta Y; Burckart GJ
Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
[TBL] [Abstract][Full Text] [Related]
26. Requirements for a lead compound to become a clinical candidate.
Hefti FF
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
[TBL] [Abstract][Full Text] [Related]
27. Variations of pharmacokinetics of drugs in patients with cirrhosis.
Pena MA; Horga JF; Zapater P
Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
[TBL] [Abstract][Full Text] [Related]
28. Different black box warning labeling for same-class drugs.
Panagiotou OA; Contopoulos-Ioannidis DG; Papanikolaou PN; Ntzani EE; Ioannidis JP
J Gen Intern Med; 2011 Jun; 26(6):603-10. PubMed ID: 21286838
[TBL] [Abstract][Full Text] [Related]
29. Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU).
Boudes PF
Drugs R D; 2017 Jun; 17(2):245-254. PubMed ID: 28160230
[TBL] [Abstract][Full Text] [Related]
30. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
31. Microdosing Studies in Children: A US Regulatory Perspective.
Roth-Cline M; Nelson RM
Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
[TBL] [Abstract][Full Text] [Related]
32. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
Kalgutkar AS; Didiuk MT
Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
[TBL] [Abstract][Full Text] [Related]
33. Strategies for dealing with reactive intermediates in drug discovery and development.
Nassar AE; Lopez-Anaya A
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
[TBL] [Abstract][Full Text] [Related]
34. [Recent findings regarding the mechanism of idiosyncratic drug toxicity].
Ikeda T
Yakugaku Zasshi; 2015; 135(4):567-78. PubMed ID: 25832837
[TBL] [Abstract][Full Text] [Related]
35. Mass spectrometry imaging in drug development.
Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
[No Abstract] [Full Text] [Related]
36. Editorial: Recent Advances in Developmental Drug Disposition.
Collier AC
Drug Metab Lett; 2015; 9(2):64. PubMed ID: 26517862
[No Abstract] [Full Text] [Related]
37. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
Velenosi TJ; Urquhart BL
Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetic and metabolic studies in the development of drugs].
Vereczkey L
Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
[TBL] [Abstract][Full Text] [Related]
39. Toxicology Strategies for Drug Discovery - Present and Future: Introduction.
Humphreys WG; Will Y; Guengerich FP
Chem Res Toxicol; 2016 Apr; 29(4):437. PubMed ID: 27087588
[No Abstract] [Full Text] [Related]
40. Practical approaches to resolving reactive metabolite liabilities in early discovery.
Dalvie D; Kalgutkar AS; Chen W
Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
